How do you pay?

How to pay the least

Ask for the cash price

Tudriqev

Tudriqev is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Tudriqev’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameTudriqev
Authorized genericvusolimogene oderparepvec-wtpg
Regular genericvusolimogene oderparepvec-wtpg
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Tudriqev?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Tudriqev’s maker. Ask the pharmacy for Tudriqev’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Tudriqev itself, from the same company, sold without the brand name, and usually for less. For now Tudriqev is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

Tudriqev is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Tudriqev’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

TUDRIQEV is a genetically modified oncolytic viral therapy indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Source: the FDA label for Tudriqev (Replimune, Inc.), August 17, 2026. Full label on DailyMed 

Good to know